MRNS - Marinus Pharmaceuticals Inc Stock Price, Fair Value and News

1.33USD+0.03 (+2.31%)Delayed

Market Summary

USD1.33+0.03

Delayed

2.31%

MRNS Alerts

CITADEL ADVISORS LLC reported owning 0% of MRNS [2024-04-25]

MRNS Stock Price

View Fullscreen

MRNS RSI Chart

MRNS Valuation

Market Cap

73.1M

Price/Earnings (Trailing)

-0.5

Price/Sales (Trailing)

2.58

EV/EBITDA

0.25

Price/Free Cashflow

-0.64

MRNS Price/Sales (Trailing)

MRNS Profitability

EBT Margin

-498.05%

Return on Equity

884.38%

Return on Assets

-105.82%

Free Cashflow Yield

-156.01%

MRNS Fundamentals

MRNS Revenue

Revenue (TTM)

28.3M

Rev. Growth (Yr)

-26.02%

Rev. Growth (Qtr)

6.8%

MRNS Earnings

Earnings (TTM)

-145.3M

Earnings Growth (Yr)

-11.34%

Earnings Growth (Qtr)

7.41%

Breaking Down MRNS Revenue

Last 30 days

-7.6%

Last 90 days

-86.6%

Trailing 12 Months

-83.6%

How does MRNS drawdown profile look like?

MRNS Financial Health

Current Ratio

3.07

MRNS Investor Care

Shares Dilution (1Y)

8.68%

Diluted EPS (TTM)

-2.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.3M	0	0	0
2023	21.7M	26.0M	31.0M	31.0M
2022	27.7M	27.6M	19.8M	25.5M
2021	3.6M	5.4M	15.4M	15.3M
2020	0	0	276.5K	1.8M
2016	72.0K	91.0K	112.0K	127.5K
2015	23.5K	37.5K	48.5K	64.0K
2014	38.6K	30.3K	21.9K	13.5K
2013	0	0	0	47.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Marinus Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	braunstein scott	acquired	214,000	4.28	50,000	chairman and ceo
Feb 20, 2024	shafer christina	sold	-20,582	9.56	-2,153	chief commercial officer
Feb 20, 2024	manning martha e	sold	-18,125	9.57	-1,894	svp, gen. counsel & corp. sec.
Feb 16, 2024	hulihan joseph	sold	-28,083	9.98	-2,814	chief medical officer
Feb 16, 2024	braunstein scott	sold	-117,789	9.94	-11,850	chairman and ceo
Feb 16, 2024	pfanstiel steven	sold	-30,827	9.97	-3,092	cfo and coo
Jan 18, 2024	manning martha e	acquired	-	-	21,835	svp, gen. counsel & corp. sec.
Jan 18, 2024	nochur sara	acquired	-	-	4,600	-
Jan 18, 2024	mayleben timothy m	acquired	-	-	4,600	-
Jan 18, 2024	ezickson elan	acquired	-	-	4,600	-

Which funds bought or sold MRNS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	reduced	-27.9	-3,246,930	4,862,840	0.53%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-34.04	-40,958	49,774	-%
May 16, 2024	COMERICA BANK	new	-	841	841	-%
May 16, 2024	JANE STREET GROUP, LLC	added	71.29	452,440	1,518,120	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	98.31	322,684	819,693	-%
May 15, 2024	Altium Capital Management LP	reduced	-11.58	-575,366	1,598,630	0.63%
May 15, 2024	Ally Bridge Group (NY) LLC	new	-	3,568,750	3,568,750	1.98%
May 15, 2024	Woodline Partners LP	added	48.35	2,032,500	10,728,500	0.10%
May 15, 2024	Bain Capital Life Sciences Investors, LLC	reduced	-2.63	-2,959,440	12,596,200	1.01%
May 15, 2024	Lion Point Capital, LP	reduced	-0.71	-4,043,250	19,157,000	10.70%

Are Funds Buying or Selling MRNS?

Are funds buying MRNS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRNS

No. of Funds

MRNS Alerts

CITADEL ADVISORS LLC reported owning 0% of MRNS [2024-04-25]

Unveiling Marinus Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	citadel advisors llc	0.0%	6	SC 13G
Apr 19, 2024	tang capital partners lp	8.2%	4,502,857	SC 13G
Feb 14, 2024	eventide asset management, llc	8.30%	4,529,997	SC 13G/A
Feb 14, 2024	lion point capital, lp	3.9%	-	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	5.96%	3,250,000	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	0.9%	493,400	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	5.8%	3,150,000	SC 13G/A
Feb 13, 2024	prudential financial inc	6.07%	0	SC 13G
Feb 13, 2024	suvretta capital management, llc	9.99%	5,463,641	SC 13G/A
Feb 08, 2024	jennison associates llc	5.4%	2,959,161	SC 13G

Recent SEC filings of Marinus Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 25, 2024	SC 13G	Major Ownership Report
Apr 19, 2024	SC 13G	Major Ownership Report
Apr 15, 2024	8-K	Current Report
Apr 04, 2024	DEF 14A	DEF 14A
Apr 04, 2024	DEFA14A	DEFA14A
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	8-K	Current Report

Peers (Alternatives to Marinus Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Marinus Pharmaceuticals Inc News

Latest updates

Marinus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	6.8%	7,679,000	7,190,000	7,338,000	6,081,000	10,380,000	7,162,000	2,340,000	1,790,000	14,186,000	1,520,000	10,114,000	1,905,000	1,806,000	1,547,000	171,000	35,500	36,000	34,000	22,000	20,000	15,000
Costs and Expenses	2.0%	43,500,000	42,627,000	38,984,000	37,520,000	43,343,000	36,374,000	32,439,000	38,556,000	30,897,000	28,636,000	29,283,000	25,390,000	28,967,000	-	-	-	-	-	-	-	-
S&GA Expenses	21.3%	18,626,000	15,358,000	14,868,000	15,722,000	15,204,000	14,658,000	13,389,000	17,061,000	11,737,000	10,622,000	9,452,000	6,828,000	10,376,000	6,005,500	4,564,000	-	-	-	-	-	-
R&D Expenses	-8.6%	24,118,000	26,382,000	23,661,000	21,412,000	27,933,000	21,424,000	19,002,000	21,495,000	17,991,000	18,014,000	18,353,000	18,562,000	18,591,000	13,044,000	11,306,000	-	-	-	-	-	-
EBITDA Margin	-9.4%	-4.36	-3.98	-0.24	-0.59	-0.13	-0.21	-4.53	-3.33	-3.40	-6.25	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	1.1%	4,346,000	4,298,000	4,242,000	4,208,000	4,147,000	3,690,000	2,634,000	2,656,000	1,692,000	1,553,000	678,000	351,000	-	-	-	98,500	118,000	124,000	124,000	121,500	121,000
Income Taxes	-	-	-	-	-1,538,000	-	-	1,752,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-41,769,000	-32,972,000	-33,472,000	-	-32,675,000	75,042,000	-39,433,000	-	-	-19,507,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	-9.5%	-4.98	-4.55	-0.78	-1.18	-0.76	-0.64	-4.98	-3.58	-3.56	-6.44	-	-	-	-	-	-	-	-	-	-	-
Net Income	7.4%	-38,669,000	-41,764,000	-32,972,000	-31,934,000	-34,730,000	-34,312,000	73,290,000	-39,433,000	-19,361,000	-28,305,000	-19,507,000	-23,823,000	-27,141,000	-17,469,000	-15,659,000	-	-	-	-	-	-
Net Income Margin	-12.6%	-5.14	-4.56	-4.33	-1.07	-1.62	-0.78	-0.70	-3.86	-3.28	-6.44	-5.72	-15.49	-21.34	-	-	-	-	-	-	-	-
Free Cashflow	-38.8%	-37,461,000	-26,992,000	-25,173,000	-24,358,000	-41,478,000	-21,914,000	-29,645,000	-33,672,000	-27,655,000	-21,750,000	5,403,000	-22,955,000	-16,183,250	-16,406,250	-14,477,250	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.6%	137	171	201	201	227	260	185	109	141	137	159	125	134	150	100	113	85.00	99.00	46.00	59.00	68.00
Current Assets	-20.6%	131	165	195	195	220	252	177	101	135	132	153	121	130	146	95.00	109	80.00	94.00	41.00	54.00	63.00
Cash Equivalents	-13.5%	104	121	140	128	147	241	168	92.00	126	123	145	112	123	139	87.00	99.00	70.00	91.00	37.00	49.00	61.00
Inventory	139.7%	6.00	2.00	3.00	3.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-2.8%	4.00	4.00	4.00	4.00	4.00	4.00	6.00	6.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-0.2%	154	154	146	144	142	144	103	105	100	83.00	80.00	30.00	19.00	13.00	12.00	12.00	13.00	11.00	12.00	12.00	10.00
Current Liabilities	5.3%	43.00	41.00	31.00	26.00	22.00	25.00	21.00	23.00	20.00	41.00	38.00	17.00	16.00	11.00	9.00	10.00	10.00	8.00	9.00	9.00	7.00
Shareholder's Equity	-198.0%	-16.43	17.00	55.00	57.00	85.00	116	82.00	5.00	40.00	53.00	78.00	95.00	115	137	87.00	101	43.00	60.00	34.00	47.00	58.00
Retained Earnings	-6.8%	-610	-571	-530	-497	-465	-430	-396	-469	-430	-410	-382	-362	-339	-311	-294	-278	-263	-235	-220	-206	-193
Additional Paid-In Capital	0.9%	594	589	585	555	546	542	474	470	466	460	457	454	450	445	373	371	306	295	254	253	252
Shares Outstanding	0.6%	55.00	55.00	55.00	51.00	50.00	50.00	37.00	37.00	37.00	37.00	37.00	37.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	545	-	-	-	179	-	-	-	452	-	-	-	303	-	-	-	207	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-38.8%	-37,461	-26,992	-25,173	-24,358	-41,478	-21,914	-29,645	-33,672	-27,655	-21,750	5,403	-22,955	-16,175	-16,398	-14,469	-16,008	-14,037	-16,249	-12,004	-8,716	-11,664
Share Based Compensation	32.3%	5,193	3,925	4,006	3,891	3,741	3,799	3,895	3,818	3,378	3,000	2,841	2,991	5,035	2,121	1,849	1,796	1,876	1,234	1,339	1,263	1,836
Cashflow From Investing	223.0%	20,885	6,466	11,920	5,004	-51,995	79.00	106,114	-335	-86.00	-721	-872	-864	1,042	2,482	2,982	495	-6,697	1,964	-255	-2,696	4,868
Cashflow From Financing	-61.1%	257	661	25,903	237	-174	94,137	-546	14.00	31,133	297	28,077	12,840	96.00	65,088	-106	44,117	117	68,069	-18.00	-	-83.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRNS Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Federal contract revenue	$ 152	$ 7,048
Total revenue	7,679	10,380
Expenses:
Research and development	24,118	27,933
Selling, general and administrative	18,626	15,204
Total expenses	43,500	43,343
Loss from operations	(35,821)	(32,963)
Interest income	1,462	2,343
Interest expense	(4,346)	(4,147)
Other income, net	36	37
Net loss applicable to common shareholders	$ (38,669)	$ (34,730)
Per share information:
Net loss per share of common stock-basic	$ (0.68)	$ (0.67)
Net loss per share of common stock-diluted	$ (0.68)	$ (0.67)
Basic weighted average shares outstanding	56,851,811	51,769,685
Diluted weighted average shares outstanding	56,851,811	51,769,685
Other comprehensive income:
Unrealized gain on available-for-sale securities	$ 20	$ 74
Total comprehensive loss	(38,649)	(34,656)
Product revenue, net
Revenue:
Revenue	7,509	3,332
Expenses:
Cost of product revenue	756	$ 206
Collaboration revenue
Revenue:
Revenue	$ 18

MRNS Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 104,253	$ 120,572
Short-term investments	9,000	29,716
Accounts receivable, net	3,513	3,799
Inventory	5,783	2,413
Prepaid expenses and other current assets	8,727	8,746
Total current assets	131,276	165,246
Property and equipment, net	3,735	3,843
Other assets	2,339	1,819
Total assets	137,350	170,908
Current liabilities:
Accounts payable	6,125	4,003
Current portion of notes payable	15,401	11,551
Current portion of revenue interest financing payable	2,511	2,211
Accrued expenses	18,721	22,859
Total current liabilities	42,758	40,624
Notes payable, net of deferred financing costs	58,072	61,423
Revenue interest financing payable, net of deferred financing costs	34,642	33,766
Contract liabilities, net	17,730	17,545
Other long-term liabilities	582	785
Total liabilities	153,784	154,143
Stockholders' equity:
Common stock, $0.001 par value; 150,000,000 shares authorized, 54,938,349 issued and 54,931,042 outstanding at March 31, 2024 and 54,585,428 issued and 54,578,121 outstanding at December 31, 2023	55	55
Additional paid-in capital	594,106	588,656
Treasury stock at cost, 7,307 shares at March 31, 2024 and December 31, 2023
Accumulated other comprehensive loss		(20)
Accumulated deficit	(610,595)	(571,926)
Total stockholders' (deficit) equity	(16,434)	16,765
Total liabilities and stockholders' (deficit) equity	$ 137,350	$ 170,908

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

CEO	Dr. Scott N. Braunstein M.D.
WEBSITE	https://marinuspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	151

Marinus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Marinus Pharmaceuticals Inc? What does MRNS stand for in stocks?

MRNS is the stock ticker symbol of Marinus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Marinus Pharmaceuticals Inc (MRNS)?

As of Fri May 17 2024, market cap of Marinus Pharmaceuticals Inc is 73.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNS stock?

You can check MRNS's fair value in chart for subscribers.

What is the fair value of MRNS stock?

You can check MRNS's fair value in chart for subscribers. The fair value of Marinus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Marinus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRNS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Marinus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MRNS is over valued or under valued. Whether Marinus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Marinus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNS.

What is Marinus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MRNS's PE ratio (Price to Earnings) is -0.5 and Price to Sales (PS) ratio is 2.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNS PE ratio will change depending on the future growth rate expectations of investors.